Clinicn Investigator Asst Prf Cancer Center, Mass General Research Institute

Assistant Professor of Medicine Harvard Medical School

Physician Medicine-Hematology and Medical Oncology, Massachusetts General Hospital

MD Harvard Medical School 1978

anthracyclines; antineoplastic agents hormonal; antineoplastic combined chemotherapy protocols; breast cancer; breast cancer clinical trials; breast neoplasms; breast tumor biomarkers; chemotherapy adjuvant; estradiol; estrogen receptor modulators; hormone therapy; neoplasms hormone-dependent; paclitaxel; receptor erbb-2 My clinical and research interests have converged on breast cancer. I have been the Principal Investigator or Site Principal Investigator in a number of clinical trials which have led to the approval of new drugs (Herceptin, Xeloda) and to the testing of promising new compounds (new antiestrogens, selective estrogen receptor modulators, novel hematopoietic growth factors and retinoids), as well as interesting compounds which may have activity in breast cancer (somatostatin analogs). I have been involved in ongoing studies of a novel breast tumor marker and have been a major investigator in a trial studying predictors of response to neoadjuvant chemotherapy. I have a particular interest in hormone therapy of breast cancer and its biological basis.